248 related articles for article (PubMed ID: 32544574)
1. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Parikh NR; Chang EM; Nickols NG; Rettig MB; Raldow AC; Steinberg ML; Koontz BF; Vapiwala N; Deville C; Feng FY; Spratt DE; Reiter RE; Phillips R; Ost P; Tran PT; Kishan AU
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):917-926. PubMed ID: 32544574
[TBL] [Abstract][Full Text] [Related]
2. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
Ramamurthy C; Handorf EA; Correa AF; Beck JR; Geynisman DM
Urol Oncol; 2019 Oct; 37(10):688-695. PubMed ID: 31399302
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.
Gupta N; Gupta D; Vaska KG; Prinja S
Appl Health Econ Health Policy; 2024 May; 22(3):415-426. PubMed ID: 38198103
[TBL] [Abstract][Full Text] [Related]
7. A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer.
De Bleser E; Willems R; Decaestecker K; Annemans L; De Bruycker A; Fonteyne V; Lumen N; Ameye F; Billiet I; Joniau S; De Meerleer G; Ost P; Bultijnck R
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947974
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
Chiang CL; So TH; Lam TC; Choi HCW
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
11. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
14. Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.
Boyd KA; Jones RJ; Paul J; Birrell F; Briggs AH; Leung HY
BMJ Open; 2015 Oct; 5(10):e007925. PubMed ID: 26482768
[TBL] [Abstract][Full Text] [Related]
15. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Hammerer P; Manka L
Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
[TBL] [Abstract][Full Text] [Related]
16. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
17. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
Liu M; Qu S; Liu Y; Yao X; Jiang W
J Comp Eff Res; 2019 Aug; 8(11):865-877. PubMed ID: 31476895
[No Abstract] [Full Text] [Related]
18. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
[TBL] [Abstract][Full Text] [Related]
19. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Yoo M; Nelson RE; Haaland B; Dougherty M; Cutshall ZA; Kohli R; Beckstead R; Kohli M
J Natl Cancer Inst; 2023 Nov; 115(11):1374-1382. PubMed ID: 37436697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
